HBM-9033
- Generic Name
- HBM-9033
A Study of SGN-MesoC2 in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic AdenocarcinomaColorectal NeoplasmsMesotheliomaOther Solid TumorsEndometrial
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 365
- Registration Number
- NCT06466187
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸The University of Kansas Clinical Research Center, Fairway, Kansas, United States
🇺🇸The University of Kansas Hospital Cambridge North Tower A, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath